<DOC>
	<DOC>NCT00770965</DOC>
	<brief_summary>This is an exploratory, 4 arm, parallel group, placebo-controlled study comparing three doses of AIN457 to placebo. Subjects with a diagnosis of moderate to severe chronic plaque psoriasis will be randomized to receive either AIN457 at one of the three doses studied or placebo.</brief_summary>
	<brief_title>Phase II Efficacy Study Looking at a Single-dose of One of Three Dose Levels of AIN457 in Patients With Chronic Plaque-type Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Diagnosis of plaque psoriasis for at least 6 months prior to screening. The patients must meet all of the following criterion: 1. Coverage of the body surface area (BSA) of 10% or more with plaques 2. A score of 3 or more on the IGA (Investigator Global Assessment) scale 3. A PASI score of at least 12 at baseline; Have forms of psoriasis other than the required "plaque psoriasis" Women of childbearing potential Recent use of investigational drugs or treatment with other biological therapies (washout periods required) Previous treatment with this investigational drug Subjects with active or history of clinically significant cardiac, kidney or liver abnormalities Other protocoldefined inclusion/exclusion criteria may have applied.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Plaque psoriasis, skin condition, thickening, flaking, skin disease, autoimmune disease</keyword>
</DOC>